BioSpace News Archive

Shares of HC2 Holdings, Inc. skyrocketed more than 51 percent in premarket trading today after Janssen Biotech Inc announced it was acquiring Rockville, Maryland-based BeneVir Biopharm, Inc., a subsidiary of HC2 in a deal that could be worth more than $1 billion.

To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth a look this month for different reasons.

It may be a bit cliche, but it’s true… if you don’t come across as confident in yourself and your abilities to do your job, how do you expect an employer to likewise feel confident making a long-term investment in you as a new employee?

Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.

While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.

Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investment overall.

Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.

As Biogen turns 40 years old, some biotech insiders and analysts seem to be concerned that the Boston-based pharmaceutical company has too many eggs in one developmental basket.

A biohacker who injected himself with an alleged experimental herpes vaccine before a crowded conference earlier this year was found dead in a Washington, D.C. sensory deprivation tank and the conspiracy theorists are running wild.

In 2015, Bristol-Myers Squibb acquired Flexus Biosciences for about $1.25 billion, picking up F001287, Flexus’ IDO1 inhibitor in the bargain, as well as its IDO/TDO discovery program. Now, Bristol-Myers has dropped two Phase III clinical trials of the IDO1 inhibitor it acquired.